{"id":"experimental-aspirin-monotherapy","safety":{"commonSideEffects":[{"rate":"1-3","effect":"Gastrointestinal bleeding"},{"rate":"5-10","effect":"Dyspepsia"},{"rate":"1-2","effect":"Bruising/bleeding"},{"rate":"<1","effect":"Allergic reaction"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aspirin acetylates serine residues on COX-1 and COX-2, preventing the synthesis of thromboxane A2 and prostaglandins. This dual action reduces platelet clumping and inflammatory mediator production, making it effective for cardiovascular protection and pain relief. As monotherapy in this context, it is used as a standalone antiplatelet agent rather than in combination regimens.","oneSentence":"Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes to reduce platelet aggregation and inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:46:08.871Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Secondary prevention of cardiovascular events (myocardial infarction, stroke)"},{"name":"Primary prevention of cardiovascular disease in high-risk patients"}]},"trialDetails":[{"nctId":"NCT07007143","phase":"PHASE4","title":"STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant","status":"RECRUITING","sponsor":"Chinese Academy of Medical Sciences, Fuwai Hospital","startDate":"2025-07-31","conditions":"Mitral Regurgitation","enrollment":1032},{"nctId":"NCT06901466","phase":"PHASE4","title":"STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients With an Indication for Oral Anticoagulant","status":"RECRUITING","sponsor":"Chinese Academy of Medical Sciences, Fuwai Hospital","startDate":"2025-06-13","conditions":"Mitral Regurgitation","enrollment":880},{"nctId":"NCT06899399","phase":"NA","title":"Efficacy and Safety Study of Endovascular Treatment of Asymptomatic Carotid Artery Stenosis","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2024-10-18","conditions":"Asymptomatic Carotid Artery Stenosis","enrollment":982},{"nctId":"NCT05763862","phase":"NA","title":"Genotype Guided Antiplatelet Therapy in Ischemic Stroke","status":"RECRUITING","sponsor":"National Neuroscience Institute","startDate":"2023-04-24","conditions":"Ischemic Stroke, Transient Ischemic Attack","enrollment":350},{"nctId":"NCT04971356","phase":"NA","title":"1-month DAPT Plus 5-month Ticagrelor Monotherapy Versus 12-month DAPT in Patients With Drug-coated Balloon","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xijing Hospital","startDate":"2021-11-01","conditions":"Antiplatelet Drug, Acute Coronary Syndrome, Angioplasty, Balloon","enrollment":1948},{"nctId":"NCT05709626","phase":"PHASE4","title":"PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction","status":"RECRUITING","sponsor":"Kindai University","startDate":"2023-02-28","conditions":"ST-segment Elevation Myocardial Infarction (STEMI)","enrollment":2258},{"nctId":"NCT01813435","phase":"PHASE3","title":"GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation","status":"COMPLETED","sponsor":"ECRI bv","startDate":"2013-07-01","conditions":"Coronary Artery Disease (CAD)","enrollment":15991},{"nctId":"NCT03231059","phase":"","title":"GLOBAL LEADERS Adjudication Sub-Study","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2017-06-01","conditions":"Coronary Artery Disease, Platelet-aggregation Inhibitors","enrollment":7365},{"nctId":"NCT03469856","phase":"NA","title":"Acetyl Salicylic Elimination Trial: The ASET Pilot Study","status":"UNKNOWN","sponsor":"Pedro A. Lemos","startDate":"2018-02-22","conditions":"Monotherapy After PCI","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":29,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Experimental: Aspirin monotherapy","genericName":"Experimental: Aspirin monotherapy","companyName":"Chinese Academy of Medical Sciences, Fuwai Hospital","companyId":"chinese-academy-of-medical-sciences-fuwai-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aspirin, a small molecule cyclooxygenase inhibitor, is used as a monotherapy for various conditions, including coronary artery disease, acute coronary syndrome, and asymptomatic carotid artery stenosis. Aspirin 100mg is administered for a month immediately after percutaneous coronary intervention (PCI) as part of best medical treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}